Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Beyond labeling: differential Ac<sub>4</sub>ManNAz dosing as a tool for functional manipulation of mesenchymal stem cells

Zhao X., Li S., Jiang X., Ma Y., Fan K., Zhang L.

Animal Study on Face & Skin, published in Regen Biomater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Regen Biomater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42088856
PMCID
PMC13138843
DOI
10.1093/rb/rbag044

Abstract (original English)

Bioorthogonal chemistry technology serves as a powerful tool for mesenchymal stem cell (MSC) transplantation by utilizing metabolic engineering for direct cell modification either in vivo or in vitro . However, the unclear effects of varying concentrations of non-natural metabolic monosaccharides on labeling efficiency, functional impact and safety pose significant challenges for clinical translation. Herein, we screened the concentration-dependent effects of the metabolic labeling agent Ac 4 ManNAz (10-100 µM) on the functionality of MSC. Visualizing azido groups on the cell surface through bioorthogonal reactions confirmed that labeling efficiency positively correlated with the concentration of Ac 4 ManNAz. Interestingly, treatment of MSC with 50-µM Ac 4 ManNAz enhances their immune regulatory function. Mechanistically, 50-µM Ac 4 ManNAz remodels the extracellular matrix of MSC by downregulating decorin (DCN) expression to alleviate TGF- β inhibition, simultaneously upregulating serglycin (SRGN) expression to activate and stabilize TGF- β . This dual action results in increased secretion of TGF- β , thereby augmenting the immune regulatory capacity of MSC. Nevertheless, at the level of cellular motility, treatment with 50-µM Ac 4 ManNAz significantly impairs the migratory capacity of MSC. Overall, this study clearly defined the concentration effect of non-natural monosacchari

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research